The new choice for the treatment of type 2 diabetes-DPP-4 inhibitors / 中国药学杂志
Chinese Pharmaceutical Journal
;
(24): 702-704, 2014.
Article
in Chinese
| WPRIM
| ID: wpr-859770
ABSTRACT
OBJECTIVE:
To review the epidemiological status of type 2 diabetes (T2DM) and therapeutic applications of incre-tin-based novel oral hypoglycemic agents.METHODS:
Based on the literatures in recent years, the mechanism and clinical evidence of DPP-4 inhibitors, particularly sitagliptin, in diabetes management were reviewed and introduced, especially sitagliptin. RESULTS ANDCONCLUSION:
DPP-4 inhibitors have many advantages and a good future in diabetes care, as either monotherapy or combination therapy. DPP-4 inhibitors have good safety profile and are recommend by some academic organizations.
Full text:
Available
Index:
WPRIM (Western Pacific)
Language:
Chinese
Journal:
Chinese Pharmaceutical Journal
Year:
2014
Type:
Article
Similar
MEDLINE
...
LILACS
LIS